Royal Liver says it is "considering carefully" the future of its investment in Park Row after the IFA posted a bigger-than-expected £2.17m loss for the first six months of the year.
The group has also announced chief executive Steve Burnett is stepping down after more than seven years after the board recommended a "change of leadership". Park Row, the subject of speculation concerning its future with Royal Liver, posted a turnover of £4.3m to the end of June, less than 70% of its anticipated budget. The speculation grew following the group's announcement it initiated a strategic review of its UK financial advice arm and Royal Liver today says it intends to focus its efforts on its manufacturing propositions Progress and Caledonian Life. "We have decided to foc...
To continue reading this article...
Join Professional Adviser for free
Signup and gain exclusive members-only insights
- Unlimited access to real-time news, industry insights and market intelligence
- Stay ahead of the curve with spotlights on emerging trends and technologies
- Receive breaking news stories straight to your inbox in the daily newsletters
- Make smart business decisions with the latest developments in regulation, investing retirement and protection
- Members-only access to the editor’s weekly Friday commentary
- Be the first to hear about our events and awards programmes
